Buzás György Miklós
Ferencvárosi Egészségügyi Szolgálat, Gasztroenterológia, Budapest.
Orv Hetil. 2004 Oct 17;145(42):2141-5.
The quality life is impaired in functional dyspepsia. Little is known, however, about the impact of different therapies on the quality of life in this condition.
The scope of this study is to detect the change-over time of the quality of life under two different treatments in functional dyspepsia.
One-hundred-one Helicobacter pylori positive and 98 Helicobacter pylori negative functional dyspepsia patients have been enrolled in a prospective, controlled study. Organic digestive diseases were excluded by endoscopy and abdominal ultrasound. The quality of life was assessed by a disease-specific questionnaire developed by the MAPI Research Institute, Lyon, France, translated and validated in Hungarian. Helicobacter pylori positive patients received one week triple regimen consisting in 2 x 40 mg pantoprazole + 2 x 1000 mg amoxicillin + 2 x 500 mg clarithromycin followed by on-demand ranitidine (1-2 x 150 mg) during 1 year of follow-up. Control 13C-urea breath test was performed 6 weeks after eradication. Helicobacter pylori negative patients received 3 x 10 mg cisapride for 6 weeks followed by on-demand prokinetic for 1 year. The questionnaire was self-administered at baseline, after 6 weeks and 1 year.
The eradication rate of Helicobacter pylori was of 76.4% on an 'intention-to treat' and 82.6% on 'per protocol' analysis. In patients with successful eradication, the standardized and transformed quality of life score increased after 6-8 weeks from 56.2 + 9.8 (95% confidence interval: 53.9-58.4) to 70.8 + 10.7 (68.3-73.5) (p = 0.0001) and to 75.3 + 9.3 (73.2-77.5) at 1 year (p = 0.005). In the patients with failed eradication, the quality of life has not been changed significantly (p = 0.76). The quality of life scores increased in Helicobacter pylori negative cases from 60.0 + 9.8 (58.0-62.0) to 73.3 + 9.6 (71.3 + 75.4) after 6 weeks (p = 0.0001) and to 76.5 + 8.5 (74.5 - 78.4) at 1 year (p = 0.56). The effect size was large in both groups and there were no differences between the treatment arms either at 6-8 weeks (p = 0.11) or after 1 year (p = 0.43).
Eradication of Helicobacter pylori infection and prokinetic treatment lead to significant improvement of the quality of life in functional dyspepsia. The disease-specific questionnaire was sensitive enough to capture the changes over time induced by the given therapies.
功能性消化不良患者的生活质量受损。然而,对于不同疗法对这种疾病患者生活质量的影响,我们了解甚少。
本研究旨在检测功能性消化不良患者在两种不同治疗方法下生活质量随时间的变化。
101例幽门螺杆菌阳性和98例幽门螺杆菌阴性的功能性消化不良患者参与了一项前瞻性对照研究。通过内镜检查和腹部超声排除器质性消化系统疾病。生活质量通过法国里昂MAPI研究所编制的特定疾病问卷进行评估,该问卷已翻译成匈牙利语并经过验证。幽门螺杆菌阳性患者接受为期一周的三联疗法,即2次40毫克泮托拉唑 + 2次1000毫克阿莫西林 + 2次500毫克克拉霉素,随后在1年的随访期间按需服用雷尼替丁(1 - 2次150毫克)。根除治疗6周后进行13C - 尿素呼气试验。幽门螺杆菌阴性患者接受6周的3次10毫克西沙必利治疗,随后1年按需服用促动力药。问卷在基线、6周和1年后由患者自行填写。
按“意向性分析”,幽门螺杆菌根除率为76.4%,按“符合方案分析”为82.6%。在根除成功的患者中,标准化和转换后的生活质量评分在6 - 8周后从56.2 + 9.8(95%置信区间:53.9 - 58.4)提高到70.8 + 10.7(68.3 - 73.5)(p = 0.0001),1年后提高到75.3 + 9.3(73.2 - 77.5)(p = 0.005)。在根除失败的患者中,生活质量无显著变化(p = 0.76)。幽门螺杆菌阴性患者的生活质量评分在6周后从60.0 + 9.8(58.0 - 62.0)提高到73.3 + 9.6(71.3 + 75.4)(p = 0.0001),1年后提高到76.5 + 8.5(74.5 - 78.4)(p = 0.56)。两组的效应量都很大,在6 - 8周时(p = 0.11)或1年后(p = 0.43),治疗组之间没有差异。
根除幽门螺杆菌感染和促动力治疗可显著改善功能性消化不良患者的生活质量。特定疾病问卷足够敏感,能够捕捉给定疗法随时间引起的变化。